# Intra-pyloric botulinum toxin injection improves liquid gastric emptying using 99mTc DTPA scintigraphy: a case report in a 2 years- old girl with idiopathic gastroparesis

**Authors:** Khadijah R Sumitro, Andy Darma, Tri P Sucianti, Stepanus Massora, Alpha F Athiyyah, Reza G Ranuh, Subijanto M Sudarmo

PMC · DOI: 10.22038/aojnmb.2025.84182.1599 · 2025-01-01

## TL;DR

A 15-month-old girl with chronic vomiting due to idiopathic gastroparesis showed significant improvement after receiving botulinum toxin injections in the pylorus.

## Contribution

This case report demonstrates the potential of intra-pyloric botulinum toxin injection as a treatment for pediatric idiopathic gastroparesis.

## Key findings

- The patient showed improved gastric emptying after the botulinum toxin injection.
- Gastric retention at 60 and 180 minutes was significantly reduced post-procedure.
- The half-time (t1/2) of gastric emptying was markedly decreased following the treatment.

## Abstract

Gastroparesis, characterized by delayed gastric emptying in the absence of mechanical obstruction, is a challenging condition to diagnose and treat in children due to limited pediatric-specific data. This case report presents a 15-month-old girl with recurrent and chronic vomiting since infancy, which worsened upon the introduction of solid foods. Initial diagnostic evaluations, including esophagogastroduodenoscopy (EGD) and upper gastrointestinal contrast study, ruled out structural abnormalities. A gastric emptying scintigraphy (GES) with 99mTc DTPA confirmed significant gastric retention, leading to a diagnosis of idiopathic gastroparesis. Endoscopic intra-pyloric botulinum toxin injection (IPBI) was performed and resulting in significant symptom improvement. Post-procedure assessments revealed improved gastric emptying, with reduced retention at 60 and 180 minutes and a markedly decreased half-time (t1/2) was shown following the procedure. These findings highlight that IPBI may be a promising therapeutic option for pediatric idiopathic gastroparesis unresponsive to standard treatments. Further research is warranted to refine treatment protocols and evaluate long-term outcomes.

## Linked entities

- **Chemicals:** 99mTc DTPA (PubChem CID 166744)
- **Diseases:** gastroparesis (MONDO:0006769), idiopathic gastroparesis (MONDO:0034150)

## Full-text entities

- **Diseases:** gastric retention (MESH:C565114), Gastroparesis (MESH:D018589), vomiting (MESH:D014839), structural abnormalities (MESH:C566527)
- **Chemicals:** Tc DTPA (MESH:D016284)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12205129/full.md

---
Source: https://tomesphere.com/paper/PMC12205129